Literature DB >> 19582521

Immunohistochemical expression of osteopontin in gastric cancer.

Motohiro Imano1, Takao Satou, Tatsuki Itoh, Kenichi Sakai, Eizaburo Ishimaru, Atsushi Yasuda, Ying-Feng Peng, Masayuki Shinkai, Fumiharu Akai, Takushi Yasuda, Haruhiko Imamoto, Kiyokata Okuno, Hiroyuki Ito, Hitoshi Shiozaki, Harumasa Ohyanagi.   

Abstract

BACKGROUND/AIMS: Osteopontin (OPN) is significantly overexpressed in a variety of malignancies. However, little is known concerning the significance of OPN expression in human cancers. Thus, the aim of this study was to determine the relationship between the degree of OPN expression, the proliferative activity of cancer cells, and the clinicopathological findings for surgically resected gastric cancer.
METHODOLOGY: We evaluated the immunohistochemical expression of OPN in 85 specimens of cancer. Additionally, we investigated a cancer cell proliferative index using an anti-MIB-1 antibody and terminal deoxynucleotidyl transferase-mediated dUTP biotin nick end labeling staining. Levels of OPN expression in gastric cancers were classified into three groups. To compare the relationship between OPN expression and clinicopathological findings, the features of cancer lesions were classified using the TNM Classification of Malignant Tumors, 6th Edition.
RESULTS: Immunohistochemical examination of OPN expression in gastric cancer revealed diffuse granular staining in the cytoplasm. High OPN expression was observed in 37 of 85 carcinomas. Strong OPN expression was significantly associated with a low apoptotic index, a high proliferative index, depth of invasion, lymphatic invasion, and venous invasion. Pathologically, intestinal type carcinoma showed strong expression of OPN.
CONCLUSIONS: These data suggested that OPN may play an important role in the invasiveness and the progressive nature of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582521     DOI: 10.1007/s11605-009-0955-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  27 in total

Review 1.  The regulation and role of osteopontin in malignant transformation and cancer.

Authors:  Mohamed K El-Tanani; Frederick Charles Campbell; Vittal Kurisetty; Dachuan Jin; Mella McCann; Philip S Rudland
Journal:  Cytokine Growth Factor Rev       Date:  2006-11-17       Impact factor: 7.638

2.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

3.  Ultrastructural immunogold localization of osteopontin in human gallbladder epithelial cells.

Authors:  L F Brown; D R Senger; L L Geng; H F Dvorak; A M Dvorak
Journal:  J Histochem Cytochem       Date:  1994-03       Impact factor: 2.479

4.  Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors.

Authors:  S A Khan; C A Lopez-Chua; J Zhang; L W Fisher; E S Sørensen; D T Denhardt
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

5.  The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas.

Authors:  D Sarkar; T Imai; F Kambe; A Shibata; S Ohmori; A Siddiq; S Hayasaka; H Funahashi; H Seo
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

Review 6.  The role of osteopontin in tumorigenesis and metastasis.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Invasion Metastasis       Date:  1997

7.  Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties.

Authors:  M T Kaartinen; A Pirhonen; A Linnala-Kankkunen; P H Mäenpää
Journal:  J Biol Chem       Date:  1999-01-15       Impact factor: 5.157

8.  Osteopontin expression and distribution in human carcinomas.

Authors:  L F Brown; A Papadopoulos-Sergiou; B Berse; E J Manseau; K Tognazzi; C A Perruzzi; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

9.  Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells.

Authors:  Gang Song; Yanlin Ming; Yubin Mao; Shideng Bao; Gaoliang Ouyang
Journal:  Exp Biol Med (Maywood)       Date:  2008-10-10

10.  Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis.

Authors:  Jian Zhao; Li Dong; Bin Lu; Guobin Wu; Dongmei Xu; Jingjing Chen; Kai Li; Xin Tong; Jianxin Dai; Side Yao; Mengchao Wu; Yajun Guo
Journal:  Gastroenterology       Date:  2008-05-07       Impact factor: 22.682

View more
  20 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma.

Authors:  Gang Wu; Jing-Jing Guo; Zhen-Yu Ma; Jie Wang; Zhong-Wen Zhou; Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

Authors:  Maria Di Bartolomeo; Filippo Pietrantonio; Alessandro Pellegrinelli; Antonia Martinetti; Luigi Mariani; Maria Grazia Daidone; Emilio Bajetta; Giuseppe Pelosi; Filippo de Braud; Irene Floriani; Rosalba Miceli
Journal:  Gastric Cancer       Date:  2015-04-11       Impact factor: 7.370

4.  Increased osteopontin-positive macrophage expression in colorectal cancer stroma with synchronous liver metastasis.

Authors:  Motohiro Imano; Kiyokata Okuno; Tatsuki Itoh; Eizaburo Ishimaru; Takao Satou; Hitoshi Shiozaki
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

5.  Platelet-derived growth factor-A and vascular endothelial growth factor-C contribute to the development of pulmonary tumor thrombotic microangiopathy in gastric cancer.

Authors:  Hiroyuki Abe; Rumi Hino; Masashi Fukayama
Journal:  Virchows Arch       Date:  2013-03-28       Impact factor: 4.064

Review 6.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

7.  Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients.

Authors:  Yue Qiu; Yuan Hu; Zuo-Yang Zhang; Lei Ye; Fei-Hong Xu; Marion E Schneider; Xue-Ling Ma; Yi-Xin Du; Xian-Bo Zuo; Fu-Sheng Zhou; Gang Chen; Xu-Shi Xie; Yan Zhang; Hong-Zhen Xia; Ji-Feng Wu; Wei-Dong Du
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-10       Impact factor: 4.553

Review 8.  Role of the metastasis-promoting protein osteopontin in the tumour microenvironment.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Mol Med       Date:  2010-07-01       Impact factor: 5.310

9.  Serum OPN expression for identification of gastric cancer and atrophic gastritis and its influencing factors.

Authors:  Tiejun Chen; Liping Sun; Caiyun He; Yuehua Gong; Qian Xu; Yuan Yuan
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

10.  The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression.

Authors:  Chang-Ni Lin; Chih-Jung Wang; Ying-Jui Chao; Ming-Derg Lai; Yan-Shen Shan
Journal:  BMC Cancer       Date:  2015-03-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.